Further experimental studies are essential to confirm the inhibitory effect of kanzonol B on CDK2 activity and to explore its functional consequences in neuronal systems and its potential as a novel therapeutic agent for epilepsy or other neurological conditions where CDK2 dysregulation plays a role. This evidence concerns the gene CDK2 and epilepsy.